SCHEMBL3253166

SCHEMBL3253166

COc1ccc(S(=O)(=O)N(c2ccc(Cl)cc2Cc2c(F)cccc2F)[C@@H](C)C(=O)O)cc1OC

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.48
PKM P14618 1/20 0.45
HCRTR1 O43613 2/20 0.43
HCRTR2 O43614 2/20 0.43
KEAP1 Q14145 6/20 0.41
NFE2L2 Q16236 3/20 0.41
MAPT P10636 3/20 0.41
SMN1; SMN2 Q16637 1/20 0.40
POLB P06746 1/20 0.40
MCOLN3 Q8TDD5 1/20 0.40
TP53 P04637 1/20 0.38
PSEN1 P49768 2/20 0.38
PSEN2 P49810 2/20 0.38
APH1B Q8WW43 2/20 0.38
NCSTN Q92542 2/20 0.38
APH1A Q96BI3 2/20 0.38
PSENEN Q9NZ42 2/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3253172 1.00 HTT (0.48) HTTPKMHCRTR1HCRTR2KEAP1
SCHEMBL8272210 0.93 PKM (0.45) HTTPKMHCRTR1HCRTR2MAPT
SCHEMBL4871558 0.92 PKM (0.46) HTTPKMHCRTR1HCRTR2MAPT
SCHEMBL3249066 0.92 PKM (0.46) HTTPKMHCRTR1HCRTR2MAPT
SCHEMBL5459745 0.92 PKM (0.46) HTTPKMHCRTR1HCRTR2KEAP1
SCHEMBL3250138 0.89 PSEN1 (0.50) PKMHCRTR1HCRTR2PSEN1PSEN2
SCHEMBL3256226 0.88 PKM (0.44) HTTPKMHCRTR1HCRTR2MAPT
SCHEMBL3249207 0.86 PKM (0.46) PKMHCRTR1HCRTR2MAPTSMN1; SMN2
SCHEMBL3247826 0.86 PKM (0.41) PKMHCRTR1HCRTR2MAPTPOLB
SCHEMBL3250706 0.86 PKM (0.41) PKMHCRTR1HCRTR2MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1776347-B1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI AVENTIS (FR) 2010-05-26 EP disclosed
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed
EP-1776347-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION Sanofi-Aventis (FR) 2007-04-25 EP disclosed
WO-2006024779-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2006-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION HCRTR2, GIPR, SSTR2 HTT 511/4885PKM 2524/4885HCRTR1 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.